# Aravax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aravax

- Industry: Biotechnology
- Headquarters: Melbourne, Australia
- Website: www.aravax.com.au/
- Total disclosed funding: $75M
- Latest round: Series B (Jan 23, 2024)
- Investors on record: 8

## About

Aravax, based in Australia, specializes in developing innovative treatments for food allergies, with a focus on peanut allergy solutions through its lead product, PVX108, leveraging advanced immunotherapy techniques.Founded in 2015 in Melbourne, Australia, Aravax is dedicated to creating therapies for food allergies. The company has successfully completed Phase 1 clinical trials for its lead product and has commenced Phase 2 trials. Recent funding includes USD 66 mn in Series B from investors such as Tenmile and Novartis Venture Fund, targeting advancements in their pioneering treatment. Aravax has conducted a total of 4 deals to date, with the most recent deal occurring on January 23, 2024.Aravax is focused on developing innovative, disease-modifying treatments for food allergies, with its lead product, PVX108, specifically targeting peanut allergies. Utilizing a proprietary platform technology, Aravax aims to reset the immune system's response to allergens, promoting long-term tolerance without inducing severe allergic reactions during treatment. Following the successful completion of Phase 1 clinical trials, Phase 2 trials have commenced and are fully recruited in clinical sites across Australia and the United States. The primary end-users of these therapies include adolescents and children diagnosed with peanut allergies, as well as their families, healthcare providers, and allergists who seek effective solutions to manage food allergy conditions. Aravax’s advancements in allergy treatments position it within a growing market of patients seeking alternative therapies, particularly in North America and select regions in Australia.Aravax's revenue generation model is based on the advancement and commercialization of its leading product, PVX108, through clinical trials and subsequent market entry. The primary transaction structure involves partnerships with healthcare institutions and clinical trial sites, where the firm conducts Phase 2 and future Phase 3 trials aimed at validating the safety and efficacy of its therapies. As these products progress through the clinical development stages, potential revenue streams are anticipated from licensing agreements, partnerships with pharmaceutical companies, and eventual sales to healthcare providers and patients. Given the specialized nature of the treatment, pricing strategies will likely reflect the high-value and novel therapeutic approaches Aravax is introducing to the food allergy domain. The focus on regulatory approvals and compliance ensures that any financial transactions linked to product sales are structured to align with industry standards and best practices.In January 2024, Aravax raised USD 66 mn in Series B funding, which will be used for product development and commercialization. The company aims to launch its lead product, PVX108, in new markets, expanding its reach into North America and select regions in Australia. The recent funding will support continued clinical trials and the progression towards market entry, with a focus on establishing partnerships to facilitate the distribution of its innovative allergy treatments.

## Funding rounds

- Series B, Jan 23, 2024, $66M — Novartis Venture Fund, Uniseed, UniSuper, Brandon Capital Partners, Tenmile, Breakthrough Victoria
- Series B, Feb 22, 2023, $9.2M — Hostplus, Medical Research Commercialisation Fund, Tenmile

## Investors

- Hostplus — Series B
- Medical Research Commercialisation Fund — Series B
- Tenmile (https://capitalatlas.ai/funds/tenmile) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Uniseed (https://capitalatlas.ai/funds/uniseed) — Series B
- UniSuper — Series B
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series B
- Breakthrough Victoria — Series B